Reviewing Developments in the World of Antibody-Drug Conjugates & Canvassing Current Perspectives on the Field

8:15 am Chairperson’s Opening Remarks

  • Puja Sapra Senior Vice President, Head R&D Biologics Engineering & Head Oncology Targeted Delivery, AstraZeneca

8:30 am Industry Leaders’ Panel Discussion

  • Puja Sapra Senior Vice President, Head R&D Biologics Engineering & Head Oncology Targeted Delivery, AstraZeneca
  • Tim Lowinger Chief Scientific & Technology Officer, Mersana Therapeutics
  • Trevor Hallam Chief Scientific Officer & President, Research, Sutro Biopharma
  • Mimi Huizinga Senior Vice President, Medical Affairs, ImmunoGen


  • Outlining the most exciting developments within the last 12 months
  • Exploring what the current clinical and commercialization landscape looks like
  • Sharing the biggest up and coming trends within the ADC field
  • Examining the next big challenges ADC developers will face

9:30 am Harnessing the Power of ADCs By Careful Selection of Target, Linker, Payload, Indication, & Combination Partner


  • Providing an overview of Seagen’s novel ADC pipeline
  • Creating best-in-class ADC opportunities through strategic pairing of target, linker, payload, and drug-antibody ratio (DAR)
  • Sharing combination strategies tailored to ADCs based on the unique mechanism of action

10:00 am Structured Networking

12:30 pm Lunch & Networking Supported by BSP Pharmaceuticals

3:00 pm Afternoon Break & Technology Slam

Analyzing Approaches to Developing & Advancing Novel ADCs into the Clinic

3:45 pm Antibody Targeted Amanitin Conjugates (ATAC): A New Payload Provides New Options for Cancer Therapy

  • Andreas Pahl Chief Scientific Officer, Heidelberg Pharma Research


  • Discussing a new payload with a new mode of action providing new options to fight cancer
  • Understanding how the ATAC platform optimized the ADC technology for that payload
  • Reviewing HDP-101 targeting BCMA; the first ATAC which cleared IND and is now in dose escalation in myeloma patients

4:15 pm Expansion of toxSYN Platform with Best-in-Class Linker Payloads Based on Validated Topiosomerase 1 Inhibitor (Exatecap) & DNA-damaging Agent (Calicheamicin)


  • Demonstrating how SYNtecan E™ and SYNeamicin G™ linker-payloads show excellent in vivo efficacy and tolerability
  • Immunogenic cell-death driven by SYNtecan E™ ADCs corroborated in syngeneic mouse models
  • Discussing how a comprehensive set of linker-payloads enables matching of payload MOA to any clinical indication

4:45 pm Understanding the Clinical Efficacy of Immune Stimulating Conjugates

  • Tim Lowinger Chief Scientific & Technology Officer, Mersana Therapeutics


  • Examining Upifitamab Rilsodotin clinical data
  • Showcasing results from the UP-NEXT, Phase III monotherapy trial in platinum sensitive recurrent ovarian cancer
  • Exploring results from XMT-1592 and XMT-1660 dose escalation trial results

5:15 pm Pan-Tumoral Small Molecule-Drug Conjugates Targeting Fibroblasts Activation Protein in Solid Lesions


  • OncoFAP is a clinically validated small organic ligand targeting FAP in solid tumors
  • Discover how OncoFAP-drug conjugates selectively target tumors in vivo and release high amount of MMAE at the site of disease
  • Explore how OncoFAP-drug conjugates potently induce anti-tumor response at doses below tumor saturation both in monotherapy and in combination with immunotherapy

5:45 pm End of Scientific Program Day One

Scientific Poster Session


After the formal presentations have finished, the learning and networking carries on. The Scientific Poster Session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session over 50 posters will be shared covering all aspects of ADC Research and development!